← Leaderboards
Rick B Meeker
University Of North Carolina Chapel Hill
$10,205,983
Attributed
$10,831,062
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $927.5K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,831,062 · 12
By mechanism
R01$8,173,138 · 6
R21$1,574,992 · 3
R43$937,619 · 2
R03$145,313 · 1
Top collaborators
- Heidi A Kay3 shared
- Lola C Hudson2 shared
- Ned C Sacktor1 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Terry A Van Dyke$19,016,013
- Elizabeth Bullitt$8,051,616
- Wenbin Lin$10,248,495
- Lishan Su$24,513,865
- Anthony S Lamantia$16,823,197
Others in their field
Top investigators on “Microglia”
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Li-Huei Tsai · Massachusetts Institute Of Technology$36,819,768
- Philip L De Jager · Columbia University Health Sciences$32,795,139
- Shilpa J Buch · University Of Kansas Medical Center$25,300,887
- Supriya Menezes · The Emmes Company, Llc$25,277,032
Research focus
MicrogliaMacrophageNeuronsIn VitroNeuronal DysfunctionRelating To Nervous SystemNerve DegenerationCalciumHiv Envelope Protein Gp120Ngfr ProteinInflammationNervous System StructureInflammatoryAlzheimer&AposPathogenesisDesignNeuraxisVirus DiseasesFeline Immunodeficiency VirusTranslationsBrainPathologyInfectionIn Vivo
Grant awards (36)
Study to establish safety, tolerability and feasibility of LM11A-31 as a neuroprotective agent in aging people living with HIV and neurocognitive impairment on antiretroviral therapy$637,932
R01 · FY2025 · AG · contact PI
Study to establish safety, tolerability and feasibility of LM11A-31 as a neuroprotective agent in aging people living with HIV and neurocognitive impairment on antiretroviral therapy$698,919
R01 · FY2023 · AG · contact PI
Neural network dysfunction in early HIV neuropathogenesis$388,750
R01 · FY2022 · NS · contact PI
Neural network dysfunction in early HIV neuropathogenesis$388,750
R01 · FY2021 · NS · contact PI
Neural network dysfunction in early HIV neuropathogenesis$388,750
R01 · FY2020 · NS · contact PI
Neural network dysfunction in early HIV neuropathogenesis$388,750
R01 · FY2019 · NS · contact PI
Neural network dysfunction in early HIV neuropathogenesis$388,750
R01 · FY2018 · NS · contact PI
A degradomics strategy for the analysis of inflammation-associated neuronal vulnerability$194,375
R21 · FY2018 · AG · contact PI
A degradomics strategy for the analysis of inflammation-associated neuronal vulnerability$233,250
R21 · FY2017 · AG · contact PI
Neurotrophin Protection in HIV and Aging$266,000
R01 · FY2016 · NS · contact PI
LM11A-31 neuroprotective efficacy in an animal model of HIV$379,050
R21 · FY2015 · NS · contact PI
Neurotrophin Protection in HIV and Aging$266,000
R01 · FY2015 · NS · contact PI
LM11A-31 neuroprotective efficacy in an animal model of HIV$391,967
R21 · FY2014 · NS · contact PI
Neurotrophin Protection in HIV and Aging$263,340
R01 · FY2014 · NS · contact PI
FIV Testing of a CNS-Relevant Antiretroviral Compound$345,048
R43 · FY2013 · MH
Neurotrophin mimetic therapeutics for HIV-associated neural dysfunction$316,483
R01 · FY2013 · MH · contact PI
Neurotrophin Protection in HIV and Aging$266,000
R01 · FY2013 · NS · contact PI
FIV Testing of a CNS-Relevant Antiretroviral Compound$344,519
R43 · FY2012 · MH
Neurotrophin mimetic therapeutics for HIV-associated neural dysfunction$329,670
R01 · FY2012 · MH · contact PI
Neurotrophin mimetic therapeutics for HIV-associated neural dysfunction$329,670
R01 · FY2011 · MH · contact PI
A Novel CNS-Penetrable Antiretroviral$248,052
R43 · FY2011 · MH
Neurotrophin mimetic therapeutics for HIV-associated neural dysfunction$333,000
R01 · FY2010 · MH · contact PI
Neurotrophin mimetic therapeutics for HIV-associated neural dysfunction$351,451
R01 · FY2009 · MH · contact PI
Choroid plexus macrophages in FIV neuropathogenesis$270,189
R01 · FY2009 · MH · contact PI
Choroid plexus macrophages in FIV neuropathogenesis$269,508
R01 · FY2008 · MH · contact PI
Neuroprotective and anti-inflammatory actions of novel growth factor mimetics$164,250
R21 · FY2008 · MH · contact PI
Choroid plexus macrophages in FIV neuropathogenesis$267,046
R01 · FY2007 · MH · contact PI
Neuroprotective and anti-inflammatory actions of novel growth factor mimetics$212,100
R21 · FY2007 · MH · contact PI
Choroid plexus macrophages in FIV neuropathogenesis$283,531
R01 · FY2006 · MH · contact PI
Microglia and choroid plexus macrophages in Neuro-AIDS$223,230
R01 · FY2005 · MH
Microglia and choroid plexus macrophages in Neuro-AIDS$223,230
R01 · FY2004 · MH
Microglia and choroid plexus macrophages in Neuro-AIDS$223,230
R01 · FY2003 · MH
Microglia and choroid plexus macrophages in Neuro-AIDS$234,605
R01 · FY2002 · MH
FIV PENETRATION AND PERSISTENCE IN NEONATAL CAT BRAIN$72,750
R03 · FY2001 · AI
EXCITATORY AMINO ACID REGULATION OF VASOPRESSIN CELLS$176,354
R01 · FY2000 · NS
FIV PENETRATION AND PERSISTENCE IN NEONATAL CAT BRAIN$72,563
R03 · FY2000 · AI